Abstract

This 2-day scientific symposium will explore emerging findings in basic science, translational research, and clinical studies to improve immunotherapeutic approaches in cancer treatment. The event will convene basic, preclinical, and clinical researchers active in the field of cancer immunotherapy, alongside industry representatives and government stakeholders. Dr. James Allison, Executive Director of the Immunotherapy Platform at the University of Texas MD Anderson Cancer Center and a pioneer in the field of cancer immunotherapy, will commence the conference with a Keynote Address. Plenary speakers will present on an array of topics, including: the evaluation of combination therapy strategies to improve clinical benefit; the development of immune-monitoring strategies for the identification of relevant prognostic and predictive biomarkers; the development of strategies to overcome immune tolerance; and the incorporation of genomics into immunotherapeutic research and clinical trials.